Comparative Pharmacology
Head-to-head clinical analysis: BUMETANIDE versus EDECRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUMETANIDE versus EDECRIN.
BUMETANIDE vs EDECRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits the Na-K-2Cl symporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.
Ethacrynic acid inhibits the Na-K-Cl cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to diuresis.
0.5-2 mg IV/IM/PO once daily; may repeat every 6-8 hours; max 10 mg/day. Continuous IV infusion: 1 mg loading dose, then 0.5-2 mg/hour.
Oral: 50-100 mg once or twice daily, maximum 400 mg/day. IV: 50 mg (0.5 mg/kg) once, may repeat once at 2-hour intervals if needed.
None Documented
None Documented
Clinical Note
moderateBumetanide + Digoxin
"The risk or severity of adverse effects can be increased when Bumetanide is combined with Digoxin."
Clinical Note
moderateBumetanide + Digitoxin
"The risk or severity of adverse effects can be increased when Bumetanide is combined with Digitoxin."
Clinical Note
moderateBumetanide + Deslanoside
"The risk or severity of adverse effects can be increased when Bumetanide is combined with Deslanoside."
Clinical Note
moderateBumetanide + Acetyldigitoxin
Terminal elimination half-life is approximately 1-1.5 hours in healthy adults; prolonged to 1.5-3 hours in renal impairment.
Terminal elimination half-life is 2-4 hours; prolonged in renal impairment (up to 30 hours) and in heart failure.
Primarily renal (approximately 80% as unchanged drug), with minimal biliary/fecal excretion (about 10-20%).
Approximately 60-70% excreted unchanged in urine via glomerular filtration and tubular secretion; remaining 30-40% eliminated via biliary/fecal route.
Category A/B
Category C
Loop Diuretic
Loop Diuretic
"The risk or severity of adverse effects can be increased when Bumetanide is combined with Acetyldigitoxin."